The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...

However, patients can survive without B cells. With solid tumors ... immunosuppressive microenvironment that "can shut down ...

When thinking about the immune system, most people think about B and T cells and how they can be trained to recognize ...

The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

Multiple players are exploring whether modalities designed to combat B cell malignancies can be repurposed against lupus, ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.

Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement ... including 51% of patients with ...

Seven patients with heavily pretreated large B-cell lymphoma (LBCL) that a CD19 CAR-T therapy had not halted had received the asset in question, dubbed NKX019. Of these individuals, five achieved a ...

Stephens initiates coverage on ADC Therapeutics (ADCT), highlighting Zynlonta's potential in second-line DLBCL and a ...